Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Allergic and Nonallergic Delayed Infusion Reactions During Natalizumab Therapy

Allergic and Nonallergic Delayed Infusion Reactions During Natalizumab Therapy OBSERVATION Allergic and Nonallergic Delayed Infusion Reactions During Natalizumab Therapy Kerstin Hellwig, MD; Sebastian Schimrigk, MD; Malte Fischer, MD; Aiden Haghikia, MD; Thomas Mu¨ller, MD; Andrew Chan, MD; Ralf Gold, MD Background: The monoclonal antibody natalizumab is relapse-remitting multiple sclerosis patients treated with a novel therapeutic option in the treatment of relapsing natalizumab. forms of multiple sclerosis. In general, therapy with na- talizumab is well tolerated. Allergic reactions and acute Conclusions: Clinicians need to consider the occur- infusion reactions typically occur during or shortly af- rence of infusion reactions, with especially delayed re- ter infusion, with a peak at the second infusion. De- actions occurring more frequently than previously as- layed infusion reactions resembling serum sickness– sumed. Our cases illustrate that some of these infusion type reactions (type III reaction) are commonly reported reactions may be treated effectively with steroids and re- in other monoclonal antibody therapies (eg, infliximab duction of the infusion rate. In cases of antibody- and rituximab), but are not described yet for natali- mediated reactions, treatment should be stopped imme- zumab. diately. Results: Delayed infusion reactions occurred in 4 of 40 Arch Neurol. 2008;65(5):656-658 3-6 ONTHLY INFUSIONS OF imab and rituximab. In the case of http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA Neurology American Medical Association

Allergic and Nonallergic Delayed Infusion Reactions During Natalizumab Therapy

Download PDF
3 pages

Loading next page...
 
/lp/american-medical-association/allergic-and-nonallergic-delayed-infusion-reactions-during-natalizumab-N0gEhPfYa8

References (11)

Publisher
American Medical Association
Copyright
Copyright 2008 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
ISSN
2168-6149
eISSN
2168-6157
DOI
10.1001/archneur.65.5.656
pmid
18474743
Publisher site
See Article on Publisher Site

Abstract

OBSERVATION Allergic and Nonallergic Delayed Infusion Reactions During Natalizumab Therapy Kerstin Hellwig, MD; Sebastian Schimrigk, MD; Malte Fischer, MD; Aiden Haghikia, MD; Thomas Mu¨ller, MD; Andrew Chan, MD; Ralf Gold, MD Background: The monoclonal antibody natalizumab is relapse-remitting multiple sclerosis patients treated with a novel therapeutic option in the treatment of relapsing natalizumab. forms of multiple sclerosis. In general, therapy with na- talizumab is well tolerated. Allergic reactions and acute Conclusions: Clinicians need to consider the occur- infusion reactions typically occur during or shortly af- rence of infusion reactions, with especially delayed re- ter infusion, with a peak at the second infusion. De- actions occurring more frequently than previously as- layed infusion reactions resembling serum sickness– sumed. Our cases illustrate that some of these infusion type reactions (type III reaction) are commonly reported reactions may be treated effectively with steroids and re- in other monoclonal antibody therapies (eg, infliximab duction of the infusion rate. In cases of antibody- and rituximab), but are not described yet for natali- mediated reactions, treatment should be stopped imme- zumab. diately. Results: Delayed infusion reactions occurred in 4 of 40 Arch Neurol. 2008;65(5):656-658 3-6 ONTHLY INFUSIONS OF imab and rituximab. In the case of

Journal

JAMA Neurology – American Medical Association

Published: May 1, 2008

There are no references for this article.